Cinetica dell'iperbilirubinemia associata a indinavir

Studio caso- controllo

Translated title of the contribution: Kinetics of hyperbilirubinemia associated with indinavir: A case- control study

M. Mongiovetti, G. Barasolo, L. Rizzi, D. Zanaboni, G. Mussati, R. Maserati

Research output: Contribution to journalArticle

Abstract

Objectives: a) To evaluate the relationship between hyperbilirubinemia and other parameters such as HIV infection stage, coinfection with hepatotropic viruses and concomitant antiretroviral treatments in subjects treated with indinavir (IDV)-containing HAART; b) To describe hyperbilirubinemia kinetics in the same cohort. Materials and methods: We evaluated retrospectively a cohort of 104 HIV+ individuals treated with a IDV-containing HAART for at least 12 mos. Hyperbilirubinemia was defined as a plasmatic total bilirubin level above 2.00 mg/dL. Results: Out of 104 pts., 37 (35.6%) resulted hyperbilirubinemic; 21/37 (56.7%) belonged to CDC '93 stage A, 16/37 (43.3%) to stages B and C. HCV coinfection was demonstrated in 18/37 (48.6%). Hyperbilirubinemia arose within the first trimester of treatment in 31/37 pts. (83.7%) and peaked within the second trimester in 21/37 (56.7%). Sixteen pts. were being treated with AZT+ 3TC (43.2%), 11 with d4T+ 3TC (29.8%), 8 with d4T+ddI (21.6%) and 2 with AZT+ddI (5.4%). An elevation of aminotransferases was also documented within the first yr. of treatment in 27/37 pts. (73%).

Original languageItalian
Pages (from-to)90-93
Number of pages4
JournalGiornale Italiano di Malattie Infettive
Volume5
Issue number2
Publication statusPublished - 1999

Fingerprint

Indinavir
Hyperbilirubinemia
Case-Control Studies
Lamivudine
Highly Active Antiretroviral Therapy
Coinfection
Second Pregnancy Trimester
First Pregnancy Trimester
Centers for Disease Control and Prevention (U.S.)
Transaminases
Bilirubin
HIV Infections
Therapeutics
HIV
Viruses

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Cinetica dell'iperbilirubinemia associata a indinavir : Studio caso- controllo. / Mongiovetti, M.; Barasolo, G.; Rizzi, L.; Zanaboni, D.; Mussati, G.; Maserati, R.

In: Giornale Italiano di Malattie Infettive, Vol. 5, No. 2, 1999, p. 90-93.

Research output: Contribution to journalArticle

@article{8d85f0313d1742eaa95f1f3627124abb,
title = "Cinetica dell'iperbilirubinemia associata a indinavir: Studio caso- controllo",
abstract = "Objectives: a) To evaluate the relationship between hyperbilirubinemia and other parameters such as HIV infection stage, coinfection with hepatotropic viruses and concomitant antiretroviral treatments in subjects treated with indinavir (IDV)-containing HAART; b) To describe hyperbilirubinemia kinetics in the same cohort. Materials and methods: We evaluated retrospectively a cohort of 104 HIV+ individuals treated with a IDV-containing HAART for at least 12 mos. Hyperbilirubinemia was defined as a plasmatic total bilirubin level above 2.00 mg/dL. Results: Out of 104 pts., 37 (35.6{\%}) resulted hyperbilirubinemic; 21/37 (56.7{\%}) belonged to CDC '93 stage A, 16/37 (43.3{\%}) to stages B and C. HCV coinfection was demonstrated in 18/37 (48.6{\%}). Hyperbilirubinemia arose within the first trimester of treatment in 31/37 pts. (83.7{\%}) and peaked within the second trimester in 21/37 (56.7{\%}). Sixteen pts. were being treated with AZT+ 3TC (43.2{\%}), 11 with d4T+ 3TC (29.8{\%}), 8 with d4T+ddI (21.6{\%}) and 2 with AZT+ddI (5.4{\%}). An elevation of aminotransferases was also documented within the first yr. of treatment in 27/37 pts. (73{\%}).",
keywords = "HIV infection, Hyperbilirubinemia, Indinavir",
author = "M. Mongiovetti and G. Barasolo and L. Rizzi and D. Zanaboni and G. Mussati and R. Maserati",
year = "1999",
language = "Italian",
volume = "5",
pages = "90--93",
journal = "Giornale Italiano di Malattie Infettive",
issn = "1126-9952",
publisher = "U T E T SpA",
number = "2",

}

TY - JOUR

T1 - Cinetica dell'iperbilirubinemia associata a indinavir

T2 - Studio caso- controllo

AU - Mongiovetti, M.

AU - Barasolo, G.

AU - Rizzi, L.

AU - Zanaboni, D.

AU - Mussati, G.

AU - Maserati, R.

PY - 1999

Y1 - 1999

N2 - Objectives: a) To evaluate the relationship between hyperbilirubinemia and other parameters such as HIV infection stage, coinfection with hepatotropic viruses and concomitant antiretroviral treatments in subjects treated with indinavir (IDV)-containing HAART; b) To describe hyperbilirubinemia kinetics in the same cohort. Materials and methods: We evaluated retrospectively a cohort of 104 HIV+ individuals treated with a IDV-containing HAART for at least 12 mos. Hyperbilirubinemia was defined as a plasmatic total bilirubin level above 2.00 mg/dL. Results: Out of 104 pts., 37 (35.6%) resulted hyperbilirubinemic; 21/37 (56.7%) belonged to CDC '93 stage A, 16/37 (43.3%) to stages B and C. HCV coinfection was demonstrated in 18/37 (48.6%). Hyperbilirubinemia arose within the first trimester of treatment in 31/37 pts. (83.7%) and peaked within the second trimester in 21/37 (56.7%). Sixteen pts. were being treated with AZT+ 3TC (43.2%), 11 with d4T+ 3TC (29.8%), 8 with d4T+ddI (21.6%) and 2 with AZT+ddI (5.4%). An elevation of aminotransferases was also documented within the first yr. of treatment in 27/37 pts. (73%).

AB - Objectives: a) To evaluate the relationship between hyperbilirubinemia and other parameters such as HIV infection stage, coinfection with hepatotropic viruses and concomitant antiretroviral treatments in subjects treated with indinavir (IDV)-containing HAART; b) To describe hyperbilirubinemia kinetics in the same cohort. Materials and methods: We evaluated retrospectively a cohort of 104 HIV+ individuals treated with a IDV-containing HAART for at least 12 mos. Hyperbilirubinemia was defined as a plasmatic total bilirubin level above 2.00 mg/dL. Results: Out of 104 pts., 37 (35.6%) resulted hyperbilirubinemic; 21/37 (56.7%) belonged to CDC '93 stage A, 16/37 (43.3%) to stages B and C. HCV coinfection was demonstrated in 18/37 (48.6%). Hyperbilirubinemia arose within the first trimester of treatment in 31/37 pts. (83.7%) and peaked within the second trimester in 21/37 (56.7%). Sixteen pts. were being treated with AZT+ 3TC (43.2%), 11 with d4T+ 3TC (29.8%), 8 with d4T+ddI (21.6%) and 2 with AZT+ddI (5.4%). An elevation of aminotransferases was also documented within the first yr. of treatment in 27/37 pts. (73%).

KW - HIV infection

KW - Hyperbilirubinemia

KW - Indinavir

UR - http://www.scopus.com/inward/record.url?scp=0032822493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032822493&partnerID=8YFLogxK

M3 - Articolo

VL - 5

SP - 90

EP - 93

JO - Giornale Italiano di Malattie Infettive

JF - Giornale Italiano di Malattie Infettive

SN - 1126-9952

IS - 2

ER -